Bio Pharma Dive

AUGUST 11, 2020

has already invested heavily in Moderna's vaccine, having previously committed $1 billion to fund clinical trials and manufacturing scale-up.

Vaccine 307

Vaccine Vaccination Clinical Trials Clinical Trials 307

World of DTC Marketing

DECEMBER 29, 2020

OBSERVATION: Biologics can take a long time to develop but COVID vaccines have been in development for almost 50 years and novel approaches were used to develop these vaccines. Vaccines typically take 10 to 15 years to develop, test and release to the public. The coronavirus vaccines, however, took less than a year.

Vaccine 307

Vaccine Vaccination Development Clinical Trials 307

Pharmaceutical Technology

DECEMBER 1, 2024

The HIV vaccine space has seen dwindling research activity as drug manufacturers turn to PrEP therapies for preventive treatment.

Vaccine 264

Vaccine Vaccination Manufacturing Drugs 264

Pharmaceutical Technology

NOVEMBER 17, 2023

in funding from the Bill & Melinda Gates Foundation for the bulk manufacturing of needle-free vaccines. Micron Biomedical has received $23.6m

Vaccine 264

Vaccine Vaccination Manufacturing 264

Pharmaceutical Technology

APRIL 13, 2023

The expanded licence will include the development of vaccines and therapeutic proteins beyond Covid-19 for human and animal health markets in Africa. During the Covid-19 pandemic, vaccination rates of many countries in Africa were significantly trailing the rest of the world.

Production 279

Production Vaccine Vaccination Protein 279

Pharmaceutical Technology

FEBRUARY 23, 2023

GenScript ProBio has announced a strategic collaboration with RVAC Medicines to manufacture GMP-grade plasmid DNA (pDNA) for the latter’s RVM-V001, an mRNA Covid-19 vaccine candidate. Under the agreement, GenScript ProBio will offer GMP plasmid manufacturing service for the RVM-V001 programme.

Vaccine 289

Vaccine Vaccination Gene Therapy Manufacturing 289

Bio Pharma Dive

DECEMBER 4, 2020

Moncef Slaoui, a leader of Operation Warp Speed, said he expects 100 million Americans to be vaccinated by the end of February — an ambitious target even as Moderna and Pfizer ramp up manufacturing.

Vaccine 258

Vaccine Vaccination Production Manufacturing 258

Pharmaceutical Technology

AUGUST 2, 2022

Samsung Biologics and GreenLight Biosciences have completed the initial commercial-scale engineering run for their messenger ribonucleic acid (mRNA) Covid-19 vaccine under their manufacturing collaboration. This will enable GreenLight to commercially deliver the mRNA vaccine.

Engineer 262

Engineer Vaccine Vaccination Clinical Trials 262

Pharmaceutical Technology

AUGUST 3, 2023

AAHI is developing a novel RNA vaccine that overcomes manufacturing and storage limitations to increase accessibility.

RNA 244

RNA Vaccine Vaccination Development 244

Bio Pharma Dive

SEPTEMBER 24, 2020

HHS Secretary Alex Azar said six vaccine developers involved with Operation Warp Speed had begun commercial manufacturing of their experimental shots.

Vaccine 236

Vaccine Vaccination Production Manufacturing 236

BioPharma Reporter

JANUARY 20, 2022

A new vaccine manufacturing plant has been opened in Cape Town by South Africa president Cyril Ramaphosa this week.

Manufacturing 145

Manufacturing Vaccine Vaccination 145

World of DTC Marketing

JANUARY 8, 2021

SUMMARY: Pfizer and Moderna will sell $28 billion of Covid-19 vaccines this year. Pharma companies will make an estimated $40 billion on the global COVID-19 vaccine market this year, which will be split between Johnson & Johnson, AstraZeneca, Novavax, and others. Can the FDA really control the quality of vaccine orders this big?

Vaccine 266

Vaccine Vaccination Pharma Companies Development 266

Pharmaceutical Technology

JUNE 24, 2022

Novavax has obtained emergency use authorization (EUA) for its Covid-19 vaccine, Nuvaxovid (NVX-CoV2373), from the Taiwan Food and Drug Administration for use in people of the age 18 years and above. The protein-based vaccine is engineered from the genetic sequence of the SARS-CoV-2 virus’ initial strain.

Vaccine 263

Vaccine Vaccination Clinical Trials Clinical Trials 263

Pharmaceutical Technology

SEPTEMBER 5, 2022

The National Medical Products Administration of China (NMPA) has approved CanSino Biologics ’ (CanSinoBIO) recombinant Covid-19 vaccine (Adenovirus Type 5 Vector) for inhalation, Convidecia Air, as a booster. This vaccine leverages the same adenovirus vector technological platform as Convidecia, the intramuscular version.

Vaccine 264

Vaccine Vaccination Genetic Engineering Clinical Trials 264

Pharmaceutical Technology

JUNE 6, 2023

Oragenics has secured funding from the Canadian bioresearch consortium CQDM to develop a variant-agnostic protein antigen for use in its Covid-19 intranasal vaccine. In March 2023, Oragenics and Inspirevax entered an exclusive global licence deal to develop the former’s lead intranasal Covid-19 vaccine candidate, NT-CoV2-1.

Vaccine 231

Vaccine Vaccination Development Manufacturing 231

Pharmaceutical Technology

AUGUST 17, 2022

On August 8, Pfizer and Valneva announced the initiation of a Phase III study with their Lyme disease vaccine , bringing the prospect of an injection to prevent the condition disease one step closer to reality. This means that the vaccine works against multiple serotypes of the disease, she explains. A one-size-fits-all approach.

Vaccine 299

Vaccine Vaccination Bacteria Protein 299

Pharmaceutical Technology

AUGUST 23, 2024

AstraZeneca may relocate its vaccine manufacturing plans from the UK to US as the finance minister discusses financing cuts.

Manufacturing 130

Manufacturing Vaccine Vaccination 130

Pharmaceutical Technology

DECEMBER 8, 2022

5-adapted bivalent Covid-19 vaccine for usage in children aged six months to four years. The vaccine is indicated for use as a third 3µg dose in the three-dose initial regimen for children of this age group. Earlier this month, the companies sought FDA EUA for the Omicron-adapted vaccine for use in children aged below five years.

Vaccine 246

Vaccine Vaccination Manufacturing Marketing 246

Pharmaceutical Technology

DECEMBER 19, 2023

BioNTech has inaugurated a new messenger RNA (mRNA) vaccine manufacturing facility in Kigali, Rwanda, which will have BioNTainers.

Manufacturing 130

Manufacturing Vaccine Vaccination RNA 130

Pharmaceutical Technology

AUGUST 1, 2022

GreenLight Biosciences has entered a partnership with the US National Institutes of Health (NIH) for the development of Covid-19 vaccines, which offer broader protection against new variants and with durable effects. They intend to develop vaccines that provide lasting immune responses compared to existing vaccines.

Vaccine 245

Vaccine Vaccination Development RNA 245

Pharmaceutical Technology

MAY 23, 2023

Croda Pharma has entered a strategic collaboration deal with Botanical Solution Inc (BSI) to expedite the production of sustainable pharmaceutical-grade vaccine adjuvant QS-21. The plentiful supply of QS-21 enables the production of next-generation adjuvant systems for new vaccine development.”

Vaccine 240

Vaccine Vaccination Production Life Science 240

Pharmaceutical Technology

DECEMBER 15, 2023

Biovac has received an investment and advisory package from the IFC to support vaccine manufacturing and pandemic preparedness in Africa.

Manufacturing 130

Manufacturing Vaccine Vaccination Packaging 130

Pharma Mirror

SEPTEMBER 22, 2021

Nantes, France, Naobios, a CDMO (Contract Development and Manufacturing Organization) providing bioprocess development and GMP production of clinical batches of viral vaccines BSL2/BSL3, oncolytic viruses and viral vectors, today announces the next phase in its partnership with FluGen, Inc., The company’s.

Clinical Trials 130

Clinical Trials Clinical Trials Manufacturing Vaccine 130

BioSpace

SEPTEMBER 26, 2023

The COVID-19 pandemic highlighted a need for local production of vaccines. Now, German pharma company BioNTech has said it will start manufacturing vaccines in Africa.

Manufacturing 117

Manufacturing Vaccine Vaccination Pharma Companies 117

Pharmaceutical Technology

SEPTEMBER 15, 2022

Last year was a positive year for biopharmaceutical companies, particularly those with Covid-19 vaccines. As a result of huge global sales of mRNA Covid-19 vaccines, the split in profits between Pfizer and BioNTech’s Comirnaty contributed towards revenues of $81.3bn and $22.4bn last year, respectively. YoY revenue growth.

Vaccine 272

Vaccine Vaccination Sales Generic Drugs 272

Pharmaceutical Technology

MARCH 8, 2024

SK bioscience has broken ground on a significant expansion of its vaccine manufacturing facility, L HOUSE, in South Korea.

Manufacturing 130

Manufacturing Vaccine Vaccination 130

Pharmaceutical Technology

DECEMBER 2, 2022

India’s Central Drugs Standard Control Organisation (CDSCO) has granted approval for Bharat Biotech’s BBV154 vaccine for treating Covid-19. BBV154 is claimed to be the first intra-nasal vaccine for Covid-19 in the world.

Vaccine 217

Vaccine Vaccination Clinical Trials Clinical Trials 217

Bio Pharma Dive

AUGUST 6, 2020

The Serum Institute, one of the world's largest vaccine producers, licensed Novavax's experimental shot, while Wockhardt signed on with the U.K. to help make AstraZeneca's candidate.

Vaccine 162

Vaccine Vaccination Manufacturing Licensing 162

BioPharma Reporter

APRIL 7, 2022

US company Catalent is acquiring the UKâs Vaccine Manufacturing and Innovation Centre in Harwell: a facility which had been planned to support COVID-19 and wider vaccine production and which is still under construction.

Manufacturing 109

Manufacturing Vaccine Vaccination Production 109

Pharmaceutical Technology

AUGUST 15, 2022

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted conditional authorisation for Moderna ’s Covid-19 booster vaccine, mRNA-1273.214 (Spikevax Bivalent Original/Omicron), for use in adults aged 18 years and above. It comprises mRNA-1273 (Spikevax) and a vaccine candidate that acts on the SARS-CoV-2 virus’ BA.1

Vaccine 214

Vaccine Vaccination Immune Response Clinical Trials 214

BioPharma Reporter

DECEMBER 14, 2021

Moderna and the Australian Government have announced an agreement in principle to build a mRNA vaccine manufacturing facility in Victoria, Australia: providing up to 100 million doses a year.

Manufacturing 119

Manufacturing Vaccine Vaccination 119

BioPharma Reporter

AUGUST 11, 2021

Moderna has signed a Memorandum of Understanding with the government of Canada to build a mRNA vaccine manufacturing facility in the country: which could serve as a model for similar partnerships around the world.

Manufacturing 116

Manufacturing Vaccine Vaccination 116

Pharmaceutical Technology

MARCH 11, 2025

MSD has opened a $1bn facility in Durham located in the US state of North Carolina, to increase vaccine manufacturing capacity.

Vaccine 147

Vaccine Vaccination Production Manufacturing 147

XTalks

MAY 27, 2021

To help boost production of its COVID-19 vaccine, Moderna has enlisted the services of Samsung Biologics , a contract development and manufacturing organization (CDMO) based in South Korea. The vaccine doses are intended for countries outside the US, with manufacturing planned to commence in the third quarter of 2021.

Manufacturing 98

Manufacturing Vaccine Vaccination Production 98

BioPharma Reporter

MARCH 22, 2021

Australiaâs Therapeutic Goods Administration (TGA) has approved manufacture of the AstraZeneca COVID-19 vaccine by CSL â Seqirus: reducing the country's dependence on limited supply from abroad and allowing a wider vaccination campaign to begin.

Vaccine 110

Vaccine Vaccination Manufacturing Regulation 110

BioSpace

NOVEMBER 24, 2020

Manufacturing capacity is often decried as a major bottleneck in administering COVID-19 vaccines to a global population of 7.8 For mRNA vaccines, the bottleneck is the availability of raw materials, not bioreactors.

Manufacturing 99

Manufacturing Vaccine Vaccination 99

BioPharma Reporter

NOVEMBER 7, 2023

The Australian biotech GPN Vaccines has expanded a partnership with compatriot contract development and manufacturing organization (CDMO) BioCina to scale up the manufacture of its lead candidate vaccine against pneumococcal diseases such as pneumonia, meningitis and febrile bacteraemia.

Manufacturing 98

Manufacturing Vaccine Vaccination Development 98